BioSpace News Archive

Ablaze Pharmaceuticals (“Ablaze”), a clinical-stage pharmaceutical company focused on the development and commercialization of innovative targeted radiopharmaceutical therapies (TRT) against tumor targets, announced a $75 million Series A financing round.

IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the appointment of Mrs. Merav Nir Dotan to the new position of Vice President, Human Resources.

Ascelia Pharma AB (publ) is presenting a study in which Orviglance® (manganese chloride tetrahydrate, former working name Mangoral) was compared against a gadolinium-based contrast agent at the world’s largest radiology conference, RSNA, in Chicago, Illinois.

CPhI awards the first ever CPhI Verified certificate to Medinfar – an international pharmaceutical manufacturer of Rx, cosmetics, food supplements and veterinary products.

Self-management programs can help adolescents living with juvenile idiopathic arthritis manage their disease as they enter adulthood, according to new research.

Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their participation at the Cytokine-Based Cancer Immunotherapies Summit occurring November 30th to December 2nd, 2021 in Boston, MA.

AB Science SA (Euronext - FR0010557264 - AB) today announced that the first patient has been dosed in the phase 2 trial evaluating the antiviral activity of masitinib in patients who have a confirmed diagnosis of COVID-19.

Qualigen Therapeutics, Inc. announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 5,880,000 shares of the Company’s common stock at a purchase price of $1.50 per share pursuant to a registered direct offering.

ERYTECH Pharma (Nasdaq & Euronext: ERYP),a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the granting of US patent 11,141,468, covering methods of treating solid tumors by administering methioninase and asparaginase.

Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced that it has appointed Jacob Chacko, M.D., as Chair of its Board of Directors.